All News

Physiomics plc (AIM: PYC) is pleased to announce positive developments relating to its core oncology and simulation business and to provide commentary on potential business collaborations and progress in diversifying into the personalised medicine space. For more information please click here.  ...

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it has today signed two new contracts with a global pharma company for Virtual Tumour pre-clinical predictions relating to a new oncology target. Please see here for further information...

Oxford, UK, 6th June 2017: Physiomics is pleased to announce that it will attend the Population Approach Group Europe (PAGE) Annual Conference taking place in Budapest, Hungary 7-9 June. PAGE is Europe’s premier conference focused on Quantitative Pharmacology and attracts the top biotech, pharma executives as well as academics working in the field. Physiomics will have a stand at the conference and has arranged a number...

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it has been contracted for two further extensions to a Virtual Tumour project with a major global pharmaceutical company, first announced on 1st March 2012. Please see here for more information....

Oxford, UK, 24 March 2017: The Board of Physiomics Plc (AIM: PYC), a UK-based systems biology company, today announces its financial results for the six months ended 31 December 2016. Physiomics Plc is a computational systems biology services company whose core technology, Virtual Tumour, predicts the effects of combination chemotherapy in pre-clinical and clinical settings and helps its clients to develop better drugs, faster and...

Physiomics plc (AIM: PYC) is pleased to announce that it is making good progress towards the strategic objectives announced in its most recent full year results (RNS 27th October 2016 and subsequent printed annual report circulated to shareholders). On the 5th December 2016 Physiomics announced an initial payment by Sareum for modelling carried out by the Company in 2010 to support the identification of an optimal...

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to confirm that is has been awarded the Innovate UK grant as part of its Biomedical Catalyst 2016 Feasibility Study Competition that was the subject of a provisional announcement on the 22nd November 2016. As previously disclosed, the proposed project is titled “Decision Support Systems For Stratified Cancer Treatment”. In line with the...

The Company confirms that it has agreed to issue share options to its directors, as follows: 1. 879,521 share options over ordinary shares in the Company ("Share Options") have been granted to Christophe Chassagnole under the Enterprise Management Initiative Scheme ("EMI"). The options are exercisable at a price of 2.5p each (being the price of the placing carried out by the company on the 21st September...

The Company announces that it received notice today that Dr Jim Millen, the Company's CEO, has purchased a total of 200,000 ordinary shares in the Company at a price of 2.5p per share, being the most recent placing price, as announced on 21 September 2016, adjusted for the subsequent share consolidation. Following this transaction Dr Millen owns 200,000 ordinary shares in the Company representing approximately...